Dr. Jennifer M. Suga
Claim this profileKaiser Permanente-Oakland
Area of expertise
Lung Cancer
Jennifer M. Suga has run 16 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Jennifer M. Suga has run 14 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Kaiser Permanente-Vallejo
Kaiser Permanente-Oakland
Clinical Trials Jennifer M. Suga is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
APL-101
for Lung Cancer
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
Recruiting
1 award
Phase 2
11 criteria
More about Jennifer M. Suga
Clinical Trial Related
7 years of experience running clinical trials · Led 38 trials as a Principal Investigator · 10 Active Clinical Trials
Treatments Jennifer M. Suga has experience with
- Pembrolizumab
- Carboplatin
- Atezolizumab
- Paclitaxel
- Pemetrexed
- Nivolumab
Breakdown of trials Jennifer M. Suga has run
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer M. Suga specialize in?
Jennifer M. Suga focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jennifer M. Suga currently recruiting for clinical trials?
Yes, Jennifer M. Suga is currently recruiting for 10 clinical trials in Vallejo California. If you're interested in participating, you should apply.
Are there any treatments that Jennifer M. Suga has studied deeply?
Yes, Jennifer M. Suga has studied treatments such as Pembrolizumab, Carboplatin, Atezolizumab.
What is the best way to schedule an appointment with Jennifer M. Suga?
Apply for one of the trials that Jennifer M. Suga is conducting.
What is the office address of Jennifer M. Suga?
The office of Jennifer M. Suga is located at: Kaiser Permanente-Oakland, Vallejo, California 94589 United States. This is the address for their practice at the Kaiser Permanente-Oakland.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.